PMID- 35748490
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20230325
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 62
IP  - 7
DP  - 2022 Jul
TI  - Comparative risk of pulmonary adverse events with transfusion of pathogen reduced 
      and conventional platelet components.
PG  - 1365-1376
LID - 10.1111/trf.16987 [doi]
AB  - BACKGROUND: Platelet transfusion carries risk of transfusion-transmitted 
      infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to 
      reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute 
      lung injury and acute respiratory distress syndrome (ARDS) occur with platelet 
      transfusion. STUDY DESIGN: An open label, sequential cohort study of 
      transfusion-dependent hematology-oncology patients was conducted to compare 
      pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the 
      incidence of treatment-emergent assisted mechanical ventilation (TEAMV) by 
      non-inferiority. Secondary outcomes included: time to TEAMV, ARDS, pulmonary AEs, 
      peri-transfusion AE, hemorrhagic AE, transfusion reactions (TRs), PC and red 
      blood cell (RBC) use, and mortality. RESULTS: By modified intent-to-treat (mITT), 
      1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts 
      had similar demographics, primary disease, and primary therapy. PRPC were 
      non-inferior to CPC for TEAMV (treatment difference -1.7%, 95% CI: (-3.3% to 
      -0.1%); odds ratio = 0.53, 95% CI: (0.30, 0.94). The cumulative incidence of 
      TEAMV for PRPC (2.9%) was significantly less than CPC (4.6%, p = .039). The 
      incidence of ARDS was less, but not significantly different, for PRPC (1.0% vs. 
      1.8%, p = .151; odds ratio = 0.57, 95% CI: (0.27, 1.18). AE, pulmonary AE, and 
      mortality were not different between cohorts. TRs were similar for PRPC and CPC 
      (8.3% vs. 9.7%, p = .256); and allergic TR were significantly less with PRPC 
      (p = .006). PC and RBC use were not increased with PRPC. DISCUSSION: PRPC 
      demonstrated reduced TEAMV with no excess treatment-related pulmonary morbidity.
CI  - (c) 2022 Cerus Corporation. Transfusion published by Wiley Periodicals LLC on 
      behalf of AABB.
FAU - Snyder, Edward L
AU  - Snyder EL
AD  - Yale University School of Medicine, New Haven, Connecticut, USA.
FAU - Wheeler, Allison P
AU  - Wheeler AP
AUID- ORCID: 0000-0003-3967-4873
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Refaai, Majed
AU  - Refaai M
AD  - University of Rochester Medical Center, Rochester, New York, USA.
FAU - Cohn, Claudia S
AU  - Cohn CS
AUID- ORCID: 0000-0001-9847-0470
AD  - University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
FAU - Poisson, Jessica
AU  - Poisson J
AD  - Duke University Medical Center, Durham, North Carolina, USA.
FAU - Fontaine, Magali
AU  - Fontaine M
AUID- ORCID: 0000-0001-6731-9516
AD  - University of Maryland Medical Center, Baltimore, Maryland, USA.
FAU - Sehl, Mary
AU  - Sehl M
AD  - UCLA Medical Center, Los Angeles, California, USA.
FAU - Nooka, Ajay K
AU  - Nooka AK
AD  - Emory University Medical Center, Atlanta, Georgia, USA.
FAU - Uhl, Lynne
AU  - Uhl L
AD  - Harvard University - Beth Israel Deaconess Hospital, Boston, Massachusetts, USA.
FAU - Spinella, Philip
AU  - Spinella P
AUID- ORCID: 0000-0003-1721-0541
AD  - University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Fenelus, Maly
AU  - Fenelus M
AD  - Memorial-Sloan Kettering Medical Center, New York, New York, USA.
FAU - Liles, Darla
AU  - Liles D
AD  - East Carolina University Medical Center, Greenville, North Carolina, USA.
FAU - Coyle, Thomas
AU  - Coyle T
AD  - Trihealth Medical Center, Cincinnati, Ohio, USA.
FAU - Becker, Joanne
AU  - Becker J
AD  - Roswell Park Medical Center, Buffalo, New York, USA.
FAU - Jeng, Michael
AU  - Jeng M
AD  - Stanford Medical School, Palo Alto, California, USA.
FAU - Gehrie, Eric A
AU  - Gehrie EA
AUID- ORCID: 0000-0002-5354-3899
AD  - Johns-Hopkins Medical Institute, Baltimore, Maryland, USA.
FAU - Spencer, Bryan R
AU  - Spencer BR
AUID- ORCID: 0000-0002-9008-9154
AD  - American Red Cross Scientific Affairs, Dedham, Massachusetts, USA.
FAU - Young, Pampee
AU  - Young P
AUID- ORCID: 0000-0001-5313-0376
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Johnson, Andrew
AU  - Johnson A
AD  - University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
FAU - O'Brien, Jennifer J
AU  - O'Brien JJ
AD  - Mayo Clinic Florida, Jacksonville, Florida, USA.
FAU - Schiller, Gary J
AU  - Schiller GJ
AD  - UCLA Medical Center, Los Angeles, California, USA.
FAU - Roback, John D
AU  - Roback JD
AD  - Emory University Medical Center, Atlanta, Georgia, USA.
FAU - Malynn, Elizabeth
AU  - Malynn E
AD  - Harvard University - Beth Israel Deaconess Hospital, Boston, Massachusetts, USA.
FAU - Jackups, Ronald
AU  - Jackups R
AD  - Washington University St. Louis, St. Louis, Missouri, USA.
FAU - Avecilla, Scott T
AU  - Avecilla ST
AUID- ORCID: 0000-0003-0661-9704
AD  - Memorial-Sloan Kettering Medical Center, New York, New York, USA.
FAU - Lin, Jin-Sying
AU  - Lin JS
AD  - Cerus Corporation, Concord, California, USA.
FAU - Liu, Kathy
AU  - Liu K
AD  - Cerus Corporation, Concord, California, USA.
FAU - Bentow, Stanley
AU  - Bentow S
AD  - Cerus Corporation, Concord, California, USA.
FAU - Peng, Ho-Lan
AU  - Peng HL
AD  - Cerus Corporation, Concord, California, USA.
FAU - Varrone, Jeanne
AU  - Varrone J
AD  - Cerus Corporation, Concord, California, USA.
FAU - Benjamin, Richard J
AU  - Benjamin RJ
AUID- ORCID: 0000-0001-6618-4744
AD  - Cerus Corporation, Concord, California, USA.
FAU - Corash, Laurence M
AU  - Corash LM
AUID- ORCID: 0000-0002-8615-9869
AD  - Cerus Corporation, Concord, California, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220624
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Photosensitizing Agents)
SB  - IM
MH  - Blood Platelets
MH  - Blood Transfusion
MH  - Cohort Studies
MH  - Humans
MH  - Photosensitizing Agents
MH  - Platelet Transfusion/adverse effects
MH  - *Respiratory Distress Syndrome/etiology/therapy
MH  - *Transfusion Reaction/epidemiology/etiology
PMC - PMC9544211
OTO - NOTNLM
OT  - assisted mechanical ventilation
OT  - pathogen reduction
OT  - platelet transfusion
OT  - pulmonary adverse events
COIS- Edward L. Snyder, Allison P Wheeler, Majed Refaai, Claudia S. Cohn, Jessica 
      Poisson, Magali Fontaine, Mary Sehl, Ajay K. Nooka, Lynne Uhl, Philip Spinella, 
      Maly Fenelus, Darla Liles, Thomas Coyle, Joanne Becker, Michael Jeng, Eric A. 
      Gehrie, Bryan R. Spencer, Pampee Young, Andrew Johnson, Jennifer J. O'Brien, Gary 
      J. Schiller, John D. Roback, Elizabeth Malynn, Ronald Jackups, and Scott T. 
      Avecilla have no personal conflicts of interest. They served as study 
      investigators and were compensated through their respective institutional 
      research contracts with Cerus Corporation. Jin-Sying Lin, Kathy Liu, Stanley 
      Bentow, and Ho-Lan Peng are employees of Cerus Corporation, the study sponsor, 
      and received compensation and equity options as part of their employment. Jeanne 
      Varrone, Richard J. Benjamin, and Laurence M. Corash are employees of Cerus 
      Corporation, the study sponsor, and received compensation and equity options as 
      part of their employment.
EDAT- 2022/06/25 06:00
MHDA- 2022/07/14 06:00
PMCR- 2022/10/07
CRDT- 2022/06/24 07:03
PHST- 2022/05/03 00:00 [revised]
PHST- 2022/03/23 00:00 [received]
PHST- 2022/05/10 00:00 [accepted]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/06/24 07:03 [entrez]
PHST- 2022/10/07 00:00 [pmc-release]
AID - TRF16987 [pii]
AID - 10.1111/trf.16987 [doi]
PST - ppublish
SO  - Transfusion. 2022 Jul;62(7):1365-1376. doi: 10.1111/trf.16987. Epub 2022 Jun 24.